Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia
Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress
Apollomics Inc. Announces $2.0 Million Bridge Financing
Apollomics Inc. (NASDAQ:APLM) Short Interest Down 30.9% in March
Apollomics Inc. (NASDAQ:APLM) Sees Large Decline in Short Interest
Apollomics Reports First Half 2025 Financial Results
Apollomics Announces Settlement of Cayman Litigation
Apollomics Announces Changes to its Board of Directors and Composition of Committees
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation
Nasdaq Resumes Trading in Apollomics Inc.
Apollomics, Inc. Company Operational Continuity Update
Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress
Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib
Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement
Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement
Apollomics Announces Updated Strategic Focus and Leadership Team Changes
Apollomics Announces Approval of Vebreltinib in China as a First-in-Class Treatment for Gliomas with MET Fusion Gene
Apollomics Presents Vebreltinib Data at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results
Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Apollomics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Apollomics to Participate in a Fireside Chat at the B. Riley Securities' 2024 Virtual Oncology Conference
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics to Present at the 2024 Biotech Showcase
Apollomics to Participate in a Fireside Chat at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
Apollomics Announces Presentation of Vebreltinib Data at the 2023 IASLC North America Conference on Lung Cancer (NACLC)
Apollomics Announces the First Approval of Vebreltinib for MET Exon 14 Skip Non-Small Cell Lung Cancer
Apollomics Announces Two New Cohorts in Global Phase 2 SPARTA Study of Vebreltinib in Non-Small Cell Lung Cancer and Other Solid Tumors with MET Dysregulation
Why Is Apollomics (APLM) Stock Up 113% Today?
Apollomics Announces Report of Activity of Vebreltinib in Glioblastoma Multiforme (GBM) with PTPRZ-MET Fusion
Apollomics Announces Efficacy of Vebreltinib in NSCLC Patients with MetEx14 Skipping Mutation Achieving an Overall Response Rate (ORR) of 75%
Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023
Apollomics Reports First Half 2023 Financial Results and Provides Corporate Update
Apollomics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Apollomics: A Taiwanese-Origin Company With Late Stage Pipeline
The 7 Most Promising Penny Stocks to Buy in June
Why Shares of Apollomics Are Up Friday
Top 5 Health Care Stocks That Are Preparing To Pump In Q2 - AngioDynamics (NASDAQ:ANGO), Apollomics (NASDAQ:APLM)